Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

This study has been terminated.
(Drug toxicity)
Sponsor:
Collaborators:
Hospital Universitario de Fuenlabrada
M.D. Anderson Cancer Center
Hospital Universitari de Bellvitge
Information provided by (Responsible Party):
Centro Nacional de Investigaciones Oncologicas CARLOS III
ClinicalTrials.gov Identifier:
NCT01548924
First received: February 15, 2012
Last updated: January 7, 2014
Last verified: January 2014
  Purpose

The investigators plan to study the determination of the dose and the combination of antiangiogenic effect of dovitinib and cytotoxic activity of weekly paclitaxel in different types of malignant tumors.


Condition Intervention Phase
Solid Tumors
Drug: Dovitinib
Drug: Dovitinib + Paclitaxel
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus Priming With BIBF 1120 BIBF 1120 Followed by Plus Paclitaxel in Breast Cancer With HER-2 Negative Correlative Proteomic Studies. and Dynamic Image

Resource links provided by NLM:


Further study details as provided by Centro Nacional de Investigaciones Oncologicas CARLOS III:

Primary Outcome Measures:
  • Maximum tolerated dose (MTD) [ Time Frame: After priming phase (7 days) ] [ Designated as safety issue: Yes ]
    Determine the maximum tolerated dose (MTD), the recommended dose for Phase 2 and the safety and tolerability in combination with paclitaxel dovitinib weekly


Secondary Outcome Measures:
  • Pharmacokinetic interactions between paclitaxel and dovitinib [ Time Frame: Baseline and end oftreatment phase, an espected average of 16 weeks ] [ Designated as safety issue: Yes ]

    To evaluate the pharmacokinetic interactions between paclitaxel and dovitinib. Establish the sampling circuit and molecular diagnostic procedures for future expansion cohort at the recommended dose for Phase 2, focusing on patients with amplifications or mutations of drug targets.

    Other criteria for safety assessment will be the number of cycles and dose intensity of each component of the treatment regimen, changes in vital signs and results of laboratory tests during and after administration of paclitaxel and dovitinib



Estimated Enrollment: 24
Study Start Date: April 2012
Study Completion Date: August 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Priming Phase
The study treatment begins with the period of seven days of priming Phase, which is administered in monoterapi dovitinib
Drug: Dovitinib
Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
Other Name: TKI-258
Experimental: Treatment Phase
The phase of treatment with two drugs (paclitaxel dovitinib more fixed dose of 80 mg/m2 per week) will begin after a washout period of seven days after the priming phase.
Drug: Dovitinib + Paclitaxel
  • Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.
  • Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.

Each cycle will last for 28 days.

Other Names:
  • -Taxol
  • -TKI-258

Detailed Description:

This is an open label,multicenter, Phase I dose escalation study with a phase dovitinib alone for the pharmacokinetic profile and a treatment phase to evaluate the safety and tolerability of oral(po)dovitinib with paclitaxel administered intravenously (iv) (80 mg/m2 on days 1, 8, 15 and 21 every 4 weeks) in patients with malignant tumors of any histologically confirmed, not susceptible of cure, which have been treated available reference.

  Eligibility

Ages Eligible for Study:   18 Years to 76 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have signed the informed consent of study and be willing to undergo an image-guided biopsy and blood sampling for FC.
  • Men or women over 18 years.
  • Patients with solid tumors locally advanced or metastatic confirmed by histological methods or cytological, not susceptible of cure, who received the standard treatment available. Participation of patients with more active malignancy.
  • measurable or nonmeasurable disease as version 1.1. of RECIST
  • Class 0 to 2 of the ECOG
  • Have at least four weeks elapsed since the last normal or experimental antitumor treatment (six weeks for BCNU, CCNU or mitomycin C)
  • Have recovered of any toxicity (except alopecia) to grade 0 or 1 according to common terminology criteria for adverse events from the National Cancer Institute (NCI CTCAE, version 4.0).
  • Life expectancy of three months.
  • Participation of patients with more active malignancy.
  • The baseline analytical data required are:

    • Absolute neutrophil count (ANC) ≥ 1.500/mm3 [1.5 x 109/l]
    • Platelets ≥ 75.000/mm3 [75 x 109/l]
    • Hemoglobin ≥ 8.0 g / dL [80 g/l]
    • Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
    • Bilirubin ≤ 1.5 x ULN.
    • AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN (with or without liver metastases)
    • Concentration of electrolytes:
    • Potassium < LIN (3.0 mmol/l) or > ULN (5.5 mmol/l)
    • Sodium < LIN (130 mmol/l) or > ULN (150 mmol/l)
  • Women of childbearing potential must have a negative pregnancy test within 7 days prior to inclusion in the study.

Exclusion Criteria:

  • Concomitant treatment with another investigational drug within 28 days before the baseline visit.
  • Have been treated with dovitinib.
  • Women of childbearing age and biologically capable of conceiving not using two contraceptive methods very effective. Highly effective contraceptive methods (such as condom with spermicide, diaphragm with spermicide, intrauterine device) should be used by both sexes during the study and maintained for 8 weeks after the end of study treatment. Oral contraceptives, implantable, or injectable may be affected by interactions with cytochrome P450, so not considered effective in this study. Women of childbearing age, defined as sexually mature those who have not had a hysterectomy or who reached natural menopause less than 12 consecutive months (i.e., who have had menses at some time during the last 12 months) must have a negative pregnancy test within 72 hours before the start of treatment with TKI258.
  • Clinically significant heart disease (class III or IV New York Heart Association) or impaired cardiac function, comprising any of the following:

    • LVEF less than 50% or lower limit of normal (whichever is greater) to evaluate two echocardiography (ECO), or below 45% or lower limit of normal (whichever is greater) on ventriculography equilibrium radionuclide (MUGA)
    • left bundle branch block
    • Use of cardiac pacemaker must
    • Congenital Long QT Syndrome
    • History or presence of ventricular tachyarrhythmia
    • Presence of unstable atrial fibrillation (ventricular rate> 100 bpm).
    • Patients with stable atrial fibrillation may participate provided they do not meet any of the other cardiac exclusion criteria.
    • clinically significant resting bradycardia (< 50 bpm)
    • Uncontrolled hypertension (systolic pressure ≥ 150 mm Hg or diastolic pressure ≥ 100 mm Hg, with or without antihypertensive medication).
    • QTc > 480 ms on ECG screening
    • Right bundle branch block over left anterior hemiblock (bifascicular block)
    • Angina pectoris in the three months prior to start of study treatment
    • Acute myocardial infarction in the three months prior to start of study treatment
    • Other clinically significant heart disease (eg., Congestive heart failure [CHF], history of labile hypertension or poor compliance history of a pattern antihypertensive)
  • Have uncontrolled infection.
  • Diabetes mellitus (insulin or insulinoindependiente, needing chronic medication) with signs of clinically significant peripheral vascular disease.
  • History of pericarditis, pleural effusion clinically important in the 12 months preceding or current ascites requiring two or more interventions per month (both increasing dose and for the expansion).
  • clinically significant disorder of the hypothalamic-pituitary, adrenal or thyroid glands.
  • History of acute or chronic pancreatitis from any cause.
  • acute or chronic liver disease or chronic liver disease of any kind.
  • Malabsorption syndrome or uncontrolled gastrointestinal toxicity (nausea, diarrhea, vomiting) than grade 2 NCI CTCAE.
  • Any other serious medical or psychiatric disorder, acute or chronic, or analytical failure increases the risk associated with participation in the study or the drug test or interfere with the interpretation of study results and, in the opinion of investigator, prevent participation in it.
  • Treatment with any of the drugs that can prolong the QT interval (Appendix C) or polymorphic ventricular tachycardia cause which can not be suspended or replaced by a different drug before the study treatment.
  • Treatment with ketoconazole, erythromycin, carbamazepine, phenobarbital, rifampicin, phenytoin, quinidine two weeks before the baseline.
  • Major surgery within 28 days before the start of study treatment, or not having recovered from the effects of a major operation.
  • Diagnosis of HIV infection (HIV testing is not mandatory).
  • History of another primary malignancy that currently has clinical or require active intervention.
  • Patients with brain metastases detected by imaging studies (such as CT, MRI)
  • Alcohol or drug abuse.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01548924

Locations
Spain
Hospital Universitario de Bellvitge
Hospitalet de Llobregat, Barcelona, Spain, 08907
Hospital Universitario de Fuenlabrada
Fuenlabrada, Madrid, Spain, 28049
MD Anderson Cancer Centre
Madrid, Spain
Sponsors and Collaborators
Centro Nacional de Investigaciones Oncologicas CARLOS III
Hospital Universitario de Fuenlabrada
M.D. Anderson Cancer Center
Hospital Universitari de Bellvitge
Investigators
Study Director: Miguel Ángel Quintela, M.D.,PhD CNIO
Principal Investigator: Ramón Colomer, M.D.,Ph.D CNIO
  More Information

No publications provided

Responsible Party: Centro Nacional de Investigaciones Oncologicas CARLOS III
ClinicalTrials.gov Identifier: NCT01548924     History of Changes
Other Study ID Numbers: CNIO-BR-01-2011
Study First Received: February 15, 2012
Last Updated: January 7, 2014
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Centro Nacional de Investigaciones Oncologicas CARLOS III:
Patients with malignant solid tumors of any histologically confirmed, not susceptible of cure, which have received the standard treatment available

Additional relevant MeSH terms:
Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 30, 2014